Correction: Investigating the use of finerenone in children with chronic kidney disease and proteinuria: design of the FIONA and open-label extension studies
Franz Schaefer, Giovanni Montini, Hee Gyung Kang, Johan Vande Walle, Joshua Zaritsky, Michiel F. Schreuder, Mieczyslaw Litwin, Andrea Scalise, Helen Scott, James Potts, Pablo Iveli, Stefanie Breitenstein, Bradley A. Warady
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsHormonal Regulation and Hypertension · Renal Diseases and Glomerulopathies · Chronic Kidney Disease and Diabetes
Correction: Trials 25, 203 (2024)
https://doi.org/10.1186/s13063-024-08021-z
Following the publication of the original article [1], we were notified that a potential competing interest regarding consulting fees received from Bayer was inadvertently omitted from his disclosures.
Originally published sentence: "BAW discloses consultant fees from Amgen, Roche, and GSK."
Corrected sentence: "BAW discloses consultant fees from Bayer, Amgen, Roche, and GSK."
The original article has been corrected.